Lehmann, A. (2006) Ecallantide (Dyax/Genzyme). Current Opinion in Investigational Drugs, 7 (3). pp. 282-90. ISSN 1472-4472Full text not available from this repository.
Ecallantide is one of a series of small-protein kallikrein inhibitors, identified through Dyax Corp's phage display technology, that is being developed by Dyax and Genzyme as a potential subcutaneous treatment for hereditary angioedema (HAE). Dyax is also independently developing ecallantide for the reduction of peri-operative blood loss during cardiopulmonary bypass surgery. The company had expected to begin phase II clinical studies in coronary bypass graft patients in the first half of 2005; however, by October 2005, these trials had been delayed until partnership negotiations for the program were completed. A pivotal, phase III clinical trial of ecallantide in HAE began in December 2005.
|Keywords:||Analgesics, Non-Narcotic/*therapeutic use Angioneurotic Edema/*drug therapy Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use Clinical Trials, Phase III Humans Kallikreins/antagonists & inhibitors Peptides/antagonists & inhibitors/therapeutic use Recombinant Proteins/therapeutic use|
|Depositing User:||Gee Wheatley|
|Date Deposited:||16 Mar 2007|
|Last Modified:||13 Jun 2012 13:00|
|Google Scholar:||7 Citations|